
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diagnostics (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Diagnostics (Basel)</journal-id><journal-id journal-id-type="publisher-id">diagnostics</journal-id><journal-title-group><journal-title>Diagnostics</journal-title></journal-title-group><issn pub-type="epub">2075-4418</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32178485</article-id><article-id pub-id-type="pmc">7151108</article-id><article-id pub-id-type="doi">10.3390/diagnostics10030154</article-id><article-id pub-id-type="publisher-id">diagnostics-10-00154</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Clinical Significance of Tumor Size, Pathological Invasion Sites Including Urinary Collecting System and Clinically Detected Renal Vein Thrombus as Predictors for Recurrence in pT3a Localized Renal Cell Carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shimizu</surname><given-names>Takuto</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9503-7356</contrib-id><name><surname>Miyake</surname><given-names>Makito</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hori</surname><given-names>Shunta</given-names></name></contrib><contrib contrib-type="author"><name><surname>Iida</surname><given-names>Kota</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ichikawa</surname><given-names>Kazuki</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sakamoto</surname><given-names>Keiichi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Miyamoto</surname><given-names>Tatsuki</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7579-0372</contrib-id><name><surname>Nakai</surname><given-names>Yasushi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Inoue</surname><given-names>Takeshi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Anai</surname><given-names>Satoshi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tanaka</surname><given-names>Nobumichi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fujimoto</surname><given-names>Kiyohide</given-names></name><xref rid="c1-diagnostics-10-00154" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-diagnostics-10-00154">Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan; <email>takutea19@gmail.com</email> (T.S.); <email>makitomiyake@yahoo.co.jp</email> (M.M.); <email>horimaus@gmail.com</email> (S.H.); <email>kota1006ida@yahoo.co.jp</email> (K.I.); <email>aburatani40@gmail.com</email> (K.I.); <email>keitsubaki2001@yahoo.co.jp</email> (K.S.); <email>tatsuki8770@gmail.com</email> (T.M.); <email>nakaiyasushi@naramed-u.ac.jp</email> (Y.N.); <email>inoue620@naramed-u.ac.jp</email> (T.I.); <email>sanai@naramed-u.ac.jp</email> (S.A.); <email>sendo@naramed-u.ac.jp</email> (N.T.)</aff><author-notes><corresp id="c1-diagnostics-10-00154"><label>*</label>Correspondence: <email>kiyokun@naramed-u.ac.jp</email>; Tel.: +81-744-22-3051; Fax: +81-744-22-9282</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>3</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2020</year></pub-date><volume>10</volume><issue>3</issue><elocation-id>154</elocation-id><history><date date-type="received"><day>14</day><month>2</month><year>2020</year></date><date date-type="accepted"><day>10</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The recent eighth tumor-node-metastasis (TMN) staging system classifies renal cell carcinoma (RCC) with perirenal fat invasion (PFI), renal sinus fat invasion (SFI), or renal vein invasion (RVI) as stage pT3a. However, limited data are available on whether these sites have similar prognostic value or recurrence rate. We investigated the recurrence rate based on tumor size, pathological invasion sites including urinary collecting system invasion (UCSI), and clinically detected renal vein thrombus (cd-RVT) with pT3aN0M0 RCC. We retrospectively reviewed 91 patients with pT3aN0M0 RCC who underwent surgical treatment. Patients with tumor size &#x0003e; 7 cm, UCSI, three invasive sites (PFI + SFI + RVI), and cd-RVT showed a significant correlation with high recurrence rates (hazard ration (HR) 2.98, <italic>p</italic> = 0.013; HR 8.86, <italic>p</italic> &#x0003c; 0.0001; HR 14.28, <italic>p</italic> = 0.0008; and HR 4.08, <italic>p</italic> = 0.0074, respectively). In the multivariate analysis, tumor size of &#x0003e;7 cm, the presence of UCSI, and cd-RVT were the independent predictors of recurrence (HR 3.39, <italic>p</italic> = 0.043, HR 7.31, <italic>p</italic> = 0.01, HR 5.06, <italic>p</italic> = 0.018, respectively). In pT3a RCC, tumor size (7 cm cut-off), UCSI, and cd-RVT may help to provide an early diagnosis of recurrence.</p></abstract><kwd-group><kwd>renal cell carcinoma</kwd><kwd>recurrence</kwd><kwd>T3a</kwd><kwd>tumor size</kwd><kwd>urinary collecting system</kwd><kwd>renal vein thrombus</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-diagnostics-10-00154"><title>1. Introduction</title><p>Renal cell carcinoma (RCC) accounts for approximately 3% of all reported human cancers worldwide [<xref rid="B1-diagnostics-10-00154" ref-type="bibr">1</xref>]. The gold standard for the treatment of localized RCCs is radical nephrectomy (RN) or partial nephrectomy (PN). Despite complete surgical resection, &#x0003e;25% of patients progress to metastatic disease [<xref rid="B2-diagnostics-10-00154" ref-type="bibr">2</xref>]. Once metastasized, the five-year survival rate of RCC is &#x0003c;10% [<xref rid="B3-diagnostics-10-00154" ref-type="bibr">3</xref>]. Therefore, it is important to classify patients with RCC according to recurrence risk and to identify patients who need short-term follow-up and pre- or postoperative treatment with molecularly targeted drugs or immune checkpoint inhibitors. </p><p>The recent eighth edition of the Union for International Cancer Control (UICC) tumor-node-metastasis (TNM; 2017) classification system is currently used for staging RCC; pT stage is defined by tumor size and local tumor extension. Of these, pT3a RCC is pathologically heterogeneous because the eighth edition of the TNM system classifies tumors with perirenal fat invasion (PFI), renal sinus fat invasion (SFI), or renal vein invasion (RVI) as stage pT3a [<xref rid="B4-diagnostics-10-00154" ref-type="bibr">4</xref>]. Limited data are available on whether the sites of invasion have similar prognostic value or recurrence rate, and these data are controversial [<xref rid="B5-diagnostics-10-00154" ref-type="bibr">5</xref>,<xref rid="B6-diagnostics-10-00154" ref-type="bibr">6</xref>,<xref rid="B7-diagnostics-10-00154" ref-type="bibr">7</xref>,<xref rid="B8-diagnostics-10-00154" ref-type="bibr">8</xref>,<xref rid="B9-diagnostics-10-00154" ref-type="bibr">9</xref>]. Bedke et al. reported that PFI and SFI simultaneously and independently influenced cancer-specific mortality (CSM) [<xref rid="B5-diagnostics-10-00154" ref-type="bibr">5</xref>]. In contrast, Poon et al. found that there was no difference between PFI and RFI in terms of prognostic impact [<xref rid="B6-diagnostics-10-00154" ref-type="bibr">6</xref>]. Costa et al. and Baccos et al. found an increase in CSM in patients with simultaneous PFI and RVI [<xref rid="B7-diagnostics-10-00154" ref-type="bibr">7</xref>,<xref rid="B8-diagnostics-10-00154" ref-type="bibr">8</xref>].</p><p>There are also reports that cT3a needs to be divided by 7 cm as well as distinguishing cT1 and cT2 instead of invasive sites [<xref rid="B9-diagnostics-10-00154" ref-type="bibr">9</xref>]. Brookman-May et al. reported that the prognostic impact of PFI and RVI on CSS appeared to be comparable. They suggested that applying a 7 cm tumor size cut-off within another staging system may allow for enhanced prognostic discrimination of pT3a RCC [<xref rid="B9-diagnostics-10-00154" ref-type="bibr">9</xref>]. Furthermore, there are controversial studies on the prognostic role of urinary collecting system invasion (UCSI) in RCC [<xref rid="B10-diagnostics-10-00154" ref-type="bibr">10</xref>,<xref rid="B11-diagnostics-10-00154" ref-type="bibr">11</xref>]. Waalkes et al. reported that UCSI is not an independent prognostic factor for RCC [<xref rid="B10-diagnostics-10-00154" ref-type="bibr">10</xref>]. In contrast, Chen et al. argued that UCSI has a significant negative impact on overall survival and recurrence-free survival in RCC patients and could be used to predict cancer-specific survival especially in localized RCC. Thus, RCC patients with UCSI should be paid more attention by clinicians and pathologists and require close follow-up for their poor prognosis [<xref rid="B11-diagnostics-10-00154" ref-type="bibr">11</xref>]. In addition, it is unclear whether the treatment of renal vein thrombus detected by preoperative image modality should be similar to that detected by postoperative pathological findings. In this context, Ball et al. found that segmental RVI was associated with better RFS and CSS than main RVI [<xref rid="B12-diagnostics-10-00154" ref-type="bibr">12</xref>].</p><p>Therefore, we performed a comprehensive analysis to identify the predictors of recurrence after RN or PN in patients with pT3a localized RCC.</p></sec><sec id="sec2-diagnostics-10-00154"><title>2. Materials and Methods</title><sec id="sec2dot1-diagnostics-10-00154"><title>2.1. Patients Selection</title><p>We retrospectively analyzed the data of 424 patients who underwent unilateral RN or PN for RCC at our institute between 2007 and 2017. There were 91 patients with pT3aN0M0 RCC according to the 2017 TNM staging system (<xref ref-type="fig" rid="diagnostics-10-00154-f001">Figure 1</xref>). A histopathological review was conducted by an experienced uropathologist to determine the pathological T category, Fuhrman grade, infiltration (INF), the presence of necrosis, sarcomatoid variant, histological classification, lymphovascular invasion (LVI), and UCSI. Furthermore, medical imaging findings were reviewed by an experienced radiologist specializing in the urogenital system to determine the clinical T category.</p><p>Histopathologically confirmed (pN0) and clinically uninvolved lymph nodes (cN0) were defined as stage N0. All tumors were restaged according to the 2017 TNM system. The radiologist used abdominal computed tomography (CT) or magnetic resonance imaging (MRI) and chest imaging (CT or chest X-ray) for clinical staging of RCC. None of the patients received pre- or postoperative therapy. The follow-up care after surgery required chest and abdominal imaging studies (abdominal ultrasound and thoracoabdominal CT) 2&#x02013;4 times a year. Recurrence was defined as distant metastasis and local recurrence identified by CT scan.</p></sec><sec id="sec2dot2-diagnostics-10-00154"><title>2.2. Ethical Approval</title><p>This study was approved by the institutional review board (IRB) of the Nara Medical University (Nara, Japan; Medical Ethics Committee ID: NMU-1966; approval date 10 October 2019) and complied with the 1964 Helsinki Declaration and its later amendments. As data for the study were obtained through a retrospective review, a waiver of informed consent was approved by the IRB. Personal information of the subjects and donors was anonymized when necessary; the information was labeled with an identifying code to make it possible to distinguish between the individuals. Then, deidentified patient data were analyzed.</p></sec><sec id="sec2dot3-diagnostics-10-00154"><title>2.3. Statistical Analysis</title><p>For statistical analysis, the survival intervals were calculated from the date of surgery to the date of first diagnosis of metastasis (recurrence-free survival (RFS)), the date of death from cancer (CSS), or the last follow-up. Statistical analyses were performed using SPSS for Windows (version 20.0; IBM, Corp., Armonk, NY, USA). Figures were generated using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). RFS and CSS were estimated using the Kaplan&#x02013;Meier method and the log-rank test was applied to compare survival curves. The univariate and multivariate Cox proportional-hazards regression models were used to identify the predictors of recurrence. A <italic>p</italic>-value &#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec3-diagnostics-10-00154"><title>3. Results</title><sec id="sec3dot1-diagnostics-10-00154"><title>3.1. Patient Characteristics</title><p>We identified 91 patients with pT3aN0M0 RCC of the 424 RCC patients who underwent surgery at our institute from 2007 to 2017. The clinical and pathological characteristics of the 91 patients are summarized in <xref rid="diagnostics-10-00154-t001" ref-type="table">Table 1</xref>.</p><p>There were 65 men (71.4%) and 26 women (28.6%). The median age was 68 years old (range, 41&#x02013;87 years). The median follow-up period was 48 months (range, 6&#x02013;134 months). During the follow-up period, 26 patients (28.6%) experienced recurrence, and 11 patients (12.1%) died; of these, 10 (11.0%) died due to recurrence and progression of RCC. Overall, the actuarial five-year RFS rate was 65.3% and the five-year CSS rate was 88.4% (<xref ref-type="fig" rid="diagnostics-10-00154-f002">Figure 2</xref>A,B).</p><p>There were 35 patients (38.5%) with cT1 and 16 patients (17.6%) with cT2 RCC. Seven patients (7.6%) underwent PN. Clinically detected renal vein thrombus (cd-RVT) was observed in 17 patients (18.7%) but not in the remaining 74 patients (81.3%). The median tumor size was 6.4 cm (range, 1.4&#x02013;14.0 cm). The tumor size was &#x02264;7 cm in 62 patients (68.1%) and was &#x0003e;7 cm in 29 patients (31.9%). UCSI was observed in 22 patients (24.2%) but not in the remaining 69 patients (75.8%). Forty-six patients (50.5%) had RVI. PFI was observed in 34 patients (37.3%); 55 patients (60.4%) had SFI. There were 56 patients (61.5%) with infiltration in only one site, 26 (28.5%) with infiltration in two sites, and 9 (9.9%) with infiltration in three sites.</p></sec><sec id="sec3dot2-diagnostics-10-00154"><title>3.2. Exploration of Prognostic Factors for RFS and CSS</title><p>We studied the impact of tumor size, UCSI, invasion site, and renal vein thrombosis on RFS. First, we found a statistically significant difference between patients with tumor size &#x02264; 7 cm and those with tumor size &#x0003e; 7 cm, and the five-year RFS rate was 71.9% and 50.9%, respectively (hazard ratio (HR) 2.98, <italic>p</italic> = 0.013, <xref ref-type="fig" rid="diagnostics-10-00154-f003">Figure 3</xref>a). Second, there was a statistically significant difference between patients with and without UCSI, and the five-year RFS rate was 17.3% and 76.7%, respectively (HR 8.86, <italic>p</italic> &#x0003c; 0.0001, <xref ref-type="fig" rid="diagnostics-10-00154-f003">Figure 3</xref>b). Third, there was a statistically significant difference between patients with one or two invasive sites and those with three invasive sites (PFI + SFI + RVI), and the five-year RFS rate was 69.5% and 27.8%, respectively (HR 14.28, <italic>p</italic> = 0.0008, <xref ref-type="fig" rid="diagnostics-10-00154-f003">Figure 3</xref>c). Finally, we found that there was a statistically significant difference between patients with and without cd-RVT, and the five-year RFS rate was 24.9% and 74.7%, respectively (HR 4.07, <italic>p</italic> = 0.0074, <xref ref-type="fig" rid="diagnostics-10-00154-f003">Figure 3</xref>d). Further, the Cox univariate analyses showed that a high C-reactive protein (CRP), high Fuhrman grade, INF b or c, the presence of LVI, necrosis, and RVI were predictive factors for recurrence and poor prognosis. In contrast, in the univariate analysis, gender, age, histological classification, sarcomatoid variant, PFI, and SFI showed no significant difference in predicting RFS (<xref rid="diagnostics-10-00154-t002" ref-type="table">Table 2</xref>).</p><p>In multivariate analysis for recurrence, tumor size &#x0003e; 7 cm (HR 3.27, <italic>p</italic> = 0.004), the presence of UCSI (HR 4.26, <italic>p</italic> = 0.001), and cd-RVT (HR 4.10, <italic>p</italic> &#x0003c; 0.001) were found to be independent prognostic factors for predicting RFS (<xref rid="diagnostics-10-00154-t002" ref-type="table">Table 2</xref>). We limited the number of variables to three considering the potential to overfit the model due to too many variables for the number of events (26 events) in a multivariable model.</p><p>Similarly, for CSS, the univariate analysis showed that there was a statistically significant difference between patients with one or two invasive sites and those with three invasive sites, and the five-year CSS rate was 93.8% and 44.4%, respectively (HR NA, <italic>p</italic> &#x0003c; 0.0001, <xref ref-type="fig" rid="diagnostics-10-00154-f004">Figure 4</xref>c), as well as between patients with and without cd-RVT, and the five-year CSS rate was 70.5% and 92.6%, respectively (HR 5.08, <italic>p</italic> = 0.049, <xref ref-type="fig" rid="diagnostics-10-00154-f004">Figure 4</xref>d). However, there was no statistically significant difference in CSS between patients in terms of tumor size (HR 3.25, <italic>p</italic> = 0.07, <xref ref-type="fig" rid="diagnostics-10-00154-f004">Figure 4</xref>a) and the presence of USCI (HR 4.35, <italic>p</italic> = 0.07, <xref ref-type="fig" rid="diagnostics-10-00154-f004">Figure 4</xref>b). However, patients with tumor size &#x0003e; 7 cm or with USCI showed a tendency to have poor CSS. This could be due to the small sample size or the short observation period. In this study, of the 91 patients, only 10 patients died due to RCC. In the univariate analysis, gender, age, CRP, Fuhrman grade, INF, LVI, necrosis, histological classification, sarcomatoid variant, PFI, and SFI showed no significant difference in predicting CSS (<xref rid="diagnostics-10-00154-t003" ref-type="table">Table 3</xref>). We do not show the results of multivariate analysis for CSS because there are few cases of cancer death.</p><p>In addition, we performed a review on UCSI and hematuria based on preoperative urinalysis, and found a correlation between the presence of UCSI and the presence of hematuria (<xref rid="diagnostics-10-00154-t004" ref-type="table">Table 4</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-diagnostics-10-00154"><title>4. Discussion</title><p>In this study, we found that tumor size of &#x0003e;7 cm, the presence of USCI, and cd-RVT were independent predictors for the poor prognosis of metastasis or recurrence in pT3aN0M0 RCC after surgery.</p><p>According to the latest TNM classification, although T1 and T2 are classified by size, T3 is classified by the site of tumor invasion [<xref rid="B4-diagnostics-10-00154" ref-type="bibr">4</xref>]. However, several recent studies have reported that a 7 cm tumor size cut-off is useful for predicting the prognosis of pT3a RCC [<xref rid="B9-diagnostics-10-00154" ref-type="bibr">9</xref>,<xref rid="B12-diagnostics-10-00154" ref-type="bibr">12</xref>]. We examined the impact of tumor size on the risk of RFS and CSS. In this study, 91 patients with pT3aN0M0 RCC were divided into two groups; 62 patients with tumor size &#x02264; 7 cm and 29 patients with tumor size &#x0003e; 7 cm. The five-year CSS rate for patients with a tumor size &#x02264; 7 cm and &#x0003e;7 cm was 92.1% and 80.2%, respectively (HR 3.25, <italic>p</italic> = 0.07, <xref ref-type="fig" rid="diagnostics-10-00154-f004">Figure 4</xref>a). There was no statistically significant difference in CSS between the two groups; however, the patients with tumor size &#x0003e; 7 cm showed a tendency to have poor CSS. The lack of statistical significance difference may be due to the small sample size or the short observation period. The five-year RFS rate was 71.9% and 50.9% for patients with tumor size &#x02264; 7 cm and &#x0003e;7 cm, respectively (HR 2.98, <italic>p</italic> = 0.0125, <xref ref-type="fig" rid="diagnostics-10-00154-f003">Figure 3</xref>a). Furthermore, the multivariate Cox proportional-hazard analysis showed that tumor size &#x0003e; 7 cm was independently associated with an increased risk of recurrence (HR 3.27; <italic>p</italic> = 0.004). This result is consistent with the findings of Chen et al. They analyzed 163 patients with pT3aN0M0 RCC and demonstrated that patients with tumor size &#x0003e; 7 cm was associated with worse estimated five-year RFS or CSS, compared with those with tumor size &#x02264; 7 cm [<xref rid="B13-diagnostics-10-00154" ref-type="bibr">13</xref>]. In addition, they identified that tumor size was an independent predictor for RFS and CSS by the multivariate Cox proportional-hazard analysis [<xref rid="B13-diagnostics-10-00154" ref-type="bibr">13</xref>]. In the report, the size of the tumor is related to the recurrence rate: the larger is the tumor, the more likely it is to be high-grade. Conversely, those with high malignancy have high tumor growth ability and may be found in an enlarged state. In the study, compared with &#x0003c;7-cm tumor, &#x02265;7-cm tumor significantly more frequently had Fuhrman grade 3&#x02013;4 (29.7% vs. 51.6%; <italic>p</italic> = 0.009) [<xref rid="B13-diagnostics-10-00154" ref-type="bibr">13</xref>]. Brookman-may et al. reported that, compared with stage pT1&#x02013;2, patients with pT3a RCC significantly more frequently had Fuhrman grade 3&#x02013;4 (29.4% vs. 13.4%; <italic>p</italic> &#x0003c; 0.001) and had tumor with &#x0003e;7 cm size (13% vs. 39.1%; <italic>p</italic> &#x0003c; 0.001). From this, it is expected that the malignancy will worsen as the size increases, but there was no description of the actual comparison between size and Fuhrman grade [<xref rid="B9-diagnostics-10-00154" ref-type="bibr">9</xref>]. In fact, our study also showed a significant correlation between tumor size and Fuhrman grade/INF/growth pattern in the spearman r test (<xref ref-type="app" rid="app1-diagnostics-10-00154">Table S1</xref>).</p><p>In this study, we examined the pathological invasion sites (PFI, SFI and RVI). Of the three sites, only RVI showed significant differences in recurrence rates in the univariate analysis (HR 2.42, <italic>p</italic> = 0.022); however, no significant difference was found in the multivariate analysis (HR 1.73, <italic>p</italic> = 0.39). In addition, the presence or absence of any pathological invasion site was not significantly different in CSS. In contrast, the tumors invading all three sites showed significant difference in RFS (HR 14.3, <italic>p</italic> = 0.0008) and CSS (HR NA, <italic>p</italic> &#x0003c; 0.0001) in the univariate analysis, but not in the multivariate analysis. </p><p>RCC often have a pseudocapsule. It can be hypothesized that pseudocapsules may have a protective role against tumor invasion to perirenal fat. In contrast, pseudocapsules have a loss of continuity on the hilum side, I mean on the side of the renal sinus fat, and it is rich in adipose tissue and has numerous veins and lymph vessels in renal sinus. Therefore, it is theoretically thought that SFI may increase the recurrence rate, but in this study there was no significant difference between the two fat sites (SFI and PFI), as in previous report [<xref rid="B5-diagnostics-10-00154" ref-type="bibr">5</xref>,<xref rid="B6-diagnostics-10-00154" ref-type="bibr">6</xref>,<xref rid="B9-diagnostics-10-00154" ref-type="bibr">9</xref>]. Exceeding the pseudocapsule itself may increase the degree of malignancy. Minervini et al. reported that, compared with tumors free from invasion to pseudocapsule, tumors with invasion to pseudocapsule had significantly association with pathologic tumor dimensions and grade [<xref rid="B14-diagnostics-10-00154" ref-type="bibr">14</xref>]. In this study, RVI performed worse than PFI or SFI. Certainly, it is not difficult to predict that the recurrence rate seems to be higher with invasion into blood vessels than with direct invasion into fats and that the prognosis is very poor if it has all three sites invasion, as shown in this study. However, the current TNM classification does not mention the number of invasion sites. The results of this study are consistent with previous reports. Costa et al. analyzed 46 patients with pT3aNxMx RCC and Baccos et al. analyzed 122 patients with pT3aNxMx RCC. They found that an increase in CSM in patients with simultaneous PFI and RVI [<xref rid="B7-diagnostics-10-00154" ref-type="bibr">7</xref>,<xref rid="B8-diagnostics-10-00154" ref-type="bibr">8</xref>]. Furthermore, Brookman-May et al. reported the prognostic impact of PFI and RVI on CSM seems to be comparable [<xref rid="B9-diagnostics-10-00154" ref-type="bibr">9</xref>]. In any case, evaluation of these three invasive sites can play an important role in predicting the patient&#x02019;s prognosis and considering adjuvant therapy.</p><p>It is unclear whether clinically and pathologically detected renal vein thrombus should be treated the same as pT3a. Therefore, we detected renal vein thrombus not only pathologically but also through diagnostic imaging studies. As a result of cd-RVT, a tumor thrombus that remains in the renal vein and does not extend to the inferior vena cava showed significant difference in RFS (HR 4.07, <italic>p</italic> = 0.0074) and CSS (HR 5.08, <italic>p</italic> = 0.049) in the univariate analysis. Furthermore, in the multivariate analysis, cd-RVT was an independent prognostic factor for RFS (HR 4.10, <italic>p</italic> &#x0003c; 0.001). This result is consistent with the study conducted by Utsunomiya et al. in Japan [<xref rid="B15-diagnostics-10-00154" ref-type="bibr">15</xref>]. They also pointed out, based on the results of the univariate analysis, that renal vein tumor thrombus, which appears clear in diagnostic imaging studies, is a predictive factor for postoperative recurrence of pT3aN0M0 RCC. Ball et al. investigated a similar question between T3a with segmental RVI (<italic>n</italic> = 87) and T3a with main RVI (<italic>n</italic> = 64) [<xref rid="B12-diagnostics-10-00154" ref-type="bibr">12</xref>]. They reported that both RFS and CSS were significantly worse in patients with main RVI than those with segmental RVI. In the multivariate analysis, main RVI had inferior RFS and CSS compared with segmental RVI. Although segmental RVI or main RVI were determined by postoperative pathological examination, renal vein thrombus can be clinically detected preoperatively. Thus, paying attention to renal vein thrombus can lead to more adequate follow-up and use of preoperative treatment. It seems that there is no way to treat these the same among patients who underwent partial resection of cT1a tumors and those who underwent nephrectomy due to the presence of renal vein thrombus. PN used to be widely performed for the treatment of small RCC. It is unclear whether there is a difference between upstaged tumors and pT1 tumors. If the preoperative diagnosis is cT1a, even if the tumor is upstaged to pT3a, a relatively good outcome is possible. In contrast, if the preoperative diagnosis is cT1b, the risk of recurrence may increase if it is upstaged to pT3a [<xref rid="B16-diagnostics-10-00154" ref-type="bibr">16</xref>,<xref rid="B17-diagnostics-10-00154" ref-type="bibr">17</xref>]. Jeong et al. examined 896 patients with pT1 tumor and 91 patients with pT3a upstaged tumor; they reported that the two-year RFS was worse in the pT3a upstaged group than that in the pT1 group. Upstaging was associated with advanced age, cT1b stage, clinical symptoms, and a high Fuhrman grade in the multivariate analysis [<xref rid="B16-diagnostics-10-00154" ref-type="bibr">16</xref>]. Lee et al. examined 1324 patients with pT1a tumors and 43 patients with pT3a upstaged tumor; they did not find any significant predictor for RFS, CSS, or overall survival [<xref rid="B17-diagnostics-10-00154" ref-type="bibr">17</xref>].</p><p>In recent years, UCSI has been considered as a prognostic factor for RCC. Waalkes et al. assessed 1678 patients with RCC and reported that UCSI is not an independent prognostic factor for RCC [<xref rid="B10-diagnostics-10-00154" ref-type="bibr">10</xref>]. In contrast, in pT3a RCC, Chen et al. examined 218 patients with RCC and argue that UCSI needs attention as an independent poor prognostic factor [<xref rid="B11-diagnostics-10-00154" ref-type="bibr">11</xref>]. In our study, the presence of UCSI was significantly correlated with poor prognosis in the univariate analysis for RFS (HR 8.86, <italic>p</italic> &#x0003c; 0.0001) and CSS (HR 4.35, <italic>p</italic> = 0.07). In the multivariate analysis, it was identified as a prognostic factor for RFS (HR 4.26, <italic>p</italic> = 0.001). Further, we examined UCSI and hematuria via preoperative urinalysis. There is the correlation between the presence of UCSI and hematuria (<xref rid="diagnostics-10-00154-t004" ref-type="table">Table 4</xref>). Considering the results of our study on the relationship between hematuria and UCSI, preoperative hematuria could be a marker for the presence of UCSI.</p><p>In our study, we found that tumor size &#x0003e; 7 cm, the presence of USCI, and cd-RVT were independent predictors for the poor prognosis for metastasis or recurrence in patients with pT3aN0M0 RCC after surgery. These findings are useful for reviewing pT3a staging and should be taken into consideration in future prospective studies. In addition, it can form the basis of a prospective study to determine whether pre- or postoperative treatment with molecular targeted drugs or immune checkpoint inhibitors should be used. At present, it is unclear whether RCC should be treated with these therapeutic agents before or after surgery. Patients with tumor size &#x02264; 7 cm, micro or macro hematuria findings, and cd-RVT have the potential to benefit from pre- or postoperative use of molecular-targeted drugs or immune checkpoint inhibitors. Furthermore, the main purpose of postoperative follow-up is to detect recurrence and metastasis at an early stage. Early detection of recurrence and metastasis enables resection; if resection is difficult, various other treatments (immunotherapy and molecular targeted therapy) may be effective. Although the American Urological Association (AUA), National Comprehensive Cancer Network (NCCN), and European Association of Urology (EAU) guidelines recommend postoperative follow-up according to the risk, there is not sufficient evidence [<xref rid="B18-diagnostics-10-00154" ref-type="bibr">18</xref>,<xref rid="B19-diagnostics-10-00154" ref-type="bibr">19</xref>,<xref rid="B20-diagnostics-10-00154" ref-type="bibr">20</xref>]. The knowledge about predictors for recurrence can lead to adequate use of adjuvant therapy, early diagnosis of recurrence, and early intervention, resulting in improved prognosis of patients with pT3aN0M0 RCC. According to currently available TNM classification, pT3a RCC is pathologically heterogeneous. There are possibilities for improving the classification to predict prognosis more precisely.</p><p>Attention has been paid to the fact that circulating tumor cells (CTC) and cell-free tumor DNA (ctDNA) may also be useful in RCC for personalized therapy or selection of therapeutic drugs [<xref rid="B21-diagnostics-10-00154" ref-type="bibr">21</xref>].</p><p>It is interesting to see whether RVI and cd-RVT increase CTC and ctDNA, and whether there is a change in urine markers with UCSI. Smith et al. reported that detection of ctDNA in plasma was more frequent in patients with larger tumors and in those with venous tumor thrombus. It is expected that metastasis is likely to occur if there are many CTC or ctDNA [<xref rid="B22-diagnostics-10-00154" ref-type="bibr">22</xref>]. This report supports the results of our study. However, in our study, we did not pay attention to liquid biopsy. Further research is needed in CTC or ctDNA in RCC.</p><p>There were several limitations in this study. First, this study had a retrospective design, a relatively small sample size, and the follow-up period was short. Due to the small number of events (26 for RSS, 10 for CSS), we limited the number of variables for RSS considering the potential to overfit the model and did not show the multivariable analyses model for CSS. The data on the type of metastasis or treatment after relapse were not available for all patients. Hence, these factors were not analyzed. Besides, details regarding the molecular makers and nephrometry were not included in our present analysis. In contrast, laboratory data such as CRP and albumin and pathological factors such as LVI, necrosis, and sarcomatoid variant were studied. Furthermore, to the best of our knowledge, it is the first report simultaneously evaluating tumor size, USCI, and renal vein tumor thrombosis as predictors of RCC.</p></sec><sec sec-type="conclusions" id="sec5-diagnostics-10-00154"><title>5. Conclusions</title><p>Our findings reveal the significant influence of tumor size (7 cm cut-off), UCSI, and cd-RVT for the poor prognosis of metastasis or recurrence in patients with pT3aN0M0 RCC after surgery. Thus, tumor size, UCSI, and cd-RVT may be considered for inclusion in the TNM classification of stage pT3a RCC in the future. Nevertheless, further research is required to validate these findings.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank all patients who participated in this study for their important contributions. We also thank Mariko Yoshimura (Department of Urology, Nara Medical University, Nara, Japan) for invaluable help with obtaining and summarizing the data used in this study.</p></ack><app-group><app id="app1-diagnostics-10-00154"><title>Supplementary Materials</title><p>The following are available online at <uri xlink:href="https://www.mdpi.com/2075-4418/10/3/154/s1">https://www.mdpi.com/2075-4418/10/3/154/s1</uri>.</p><supplementary-material content-type="local-data" id="diagnostics-10-00154-s001"><media xlink:href="diagnostics-10-00154-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, T.S. and M.M.; methodology, T.S.; software, S.H.; validation, S.H., K.I. (Kota Iida), and M.M.; formal analysis, T.S.; investigation, T.S.; resources, K.I. (Kota Iida), Y.N., T.I., S.A., and N.T.; data curation, T.S., K.I. (Kazuki Ichikawa), K.S., and T.M.; writing&#x02014;original draft preparation, T.S.; writing&#x02014;review and editing, T.S. and S.H.; visualization, T.S.; and supervision, K.F. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research received no external funding.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-diagnostics-10-00154"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>K.D.</given-names></name><name><surname>Siegel</surname><given-names>R.L.</given-names></name><name><surname>Lin</surname><given-names>C.C.</given-names></name><name><surname>Mariotto</surname><given-names>A.B.</given-names></name><name><surname>Kramer</surname><given-names>J.L.</given-names></name><name><surname>Rowland</surname><given-names>J.H.</given-names></name><name><surname>Stein</surname><given-names>K.D.</given-names></name><name><surname>Alteri</surname><given-names>R.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Cancer treatment and survivorship statistics</article-title><source>CA Cancer J. Clin.</source><year>2016</year><volume>66</volume><fpage>271</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.3322/caac.21349</pub-id><pub-id pub-id-type="pmid">27253694</pub-id></element-citation></ref><ref id="B2-diagnostics-10-00154"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacLennan</surname><given-names>S.</given-names></name><name><surname>Imamura</surname><given-names>M.</given-names></name><name><surname>Lapitan</surname><given-names>M.C.</given-names></name><name><surname>Omar</surname><given-names>M.I.</given-names></name><name><surname>Lam</surname><given-names>T.B.</given-names></name><name><surname>Hilvano-Cabungcal</surname><given-names>A.M.</given-names></name><name><surname>Royle</surname><given-names>P.</given-names></name><name><surname>Stewart</surname><given-names>F.</given-names></name><name><surname>MacLennan</surname><given-names>G.</given-names></name><name><surname>MacLennan</surname><given-names>S.J.</given-names></name><etal/></person-group><article-title>Systematic review of oncological outcomes following surgical management of localised renal cancer</article-title><source>Eur. Urol.</source><year>2012</year><volume>61</volume><fpage>972</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2012.02.039</pub-id><pub-id pub-id-type="pmid">22405593</pub-id></element-citation></ref><ref id="B3-diagnostics-10-00154"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyake</surname><given-names>M.</given-names></name><name><surname>Kuwada</surname><given-names>M.</given-names></name><name><surname>Hori</surname><given-names>S.</given-names></name><name><surname>Morizawa</surname><given-names>Y.</given-names></name><name><surname>Tatsumi</surname><given-names>Y.</given-names></name><name><surname>Anai</surname><given-names>S.</given-names></name><name><surname>Hosokawa</surname><given-names>Y.</given-names></name><name><surname>Hayashi</surname><given-names>Y.</given-names></name><name><surname>Tomioka</surname><given-names>A.</given-names></name><name><surname>Otani</surname><given-names>T.</given-names></name><etal/></person-group><article-title>The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: A Japanese retrospective study</article-title><source>BMC Res. Notes</source><year>2016</year><volume>9</volume><elocation-id>79</elocation-id><pub-id pub-id-type="doi">10.1186/s13104-016-1895-8</pub-id><pub-id pub-id-type="pmid">26861149</pub-id></element-citation></ref><ref id="B4-diagnostics-10-00154"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>James</surname><given-names>D.</given-names></name><name><surname>Brierley</surname><given-names>M.K.G.</given-names></name></person-group><article-title>Christian Wittekind</article-title><source>TNM Classification of Malignant Tumours</source><edition>8th ed.</edition><publisher-name>Wiley</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2017</year></element-citation></ref><ref id="B5-diagnostics-10-00154"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedke</surname><given-names>J.</given-names></name><name><surname>Buse</surname><given-names>S.</given-names></name><name><surname>Pritsch</surname><given-names>M.</given-names></name><name><surname>Macher-Goeppinger</surname><given-names>S.</given-names></name><name><surname>Schirmacher</surname><given-names>P.</given-names></name><name><surname>Haferkamp</surname><given-names>A.</given-names></name><name><surname>Hohenfellner</surname><given-names>M.</given-names></name></person-group><article-title>Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: Possible prognostic differences</article-title><source>BJU Int.</source><year>2009</year><volume>103</volume><fpage>1349</fpage><lpage>1354</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2008.08236.x</pub-id><pub-id pub-id-type="pmid">19076147</pub-id></element-citation></ref><ref id="B6-diagnostics-10-00154"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poon</surname><given-names>S.A.</given-names></name><name><surname>Gonzalez</surname><given-names>J.R.</given-names></name><name><surname>Benson</surname><given-names>M.C.</given-names></name><name><surname>McKiernan</surname><given-names>J.M.</given-names></name></person-group><article-title>Invasion of renal sinus fat is not an independent predictor of survival in pT3a renal cell carcinoma</article-title><source>BJU Int.</source><year>2009</year><volume>103</volume><fpage>1622</fpage><lpage>1625</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2008.08239.x</pub-id><pub-id pub-id-type="pmid">19154464</pub-id></element-citation></ref><ref id="B7-diagnostics-10-00154"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Da Costa</surname><given-names>W.H.</given-names></name><name><surname>Moniz</surname><given-names>R.R.</given-names></name><name><surname>da Cunha</surname><given-names>I.W.</given-names></name><name><surname>Fonseca</surname><given-names>F.P.</given-names></name><name><surname>Guimaraes</surname><given-names>G.C.</given-names></name><name><surname>de Cassio Zequi</surname><given-names>S.</given-names></name></person-group><article-title>Impact of renal vein invasion and fat invasion in pT3a renal cell carcinoma</article-title><source>BJU Int.</source><year>2012</year><volume>109</volume><fpage>544</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2011.10366.x</pub-id><pub-id pub-id-type="pmid">21711437</pub-id></element-citation></ref><ref id="B8-diagnostics-10-00154"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baccos</surname><given-names>A.</given-names></name><name><surname>Brunocilla</surname><given-names>E.</given-names></name><name><surname>Schiavina</surname><given-names>R.</given-names></name><name><surname>Borghesi</surname><given-names>M.</given-names></name><name><surname>Rocca</surname><given-names>G.C.</given-names></name><name><surname>Chessa</surname><given-names>F.</given-names></name><name><surname>Saraceni</surname><given-names>G.</given-names></name><name><surname>Fiorentino</surname><given-names>M.</given-names></name><name><surname>Martorana</surname><given-names>G.</given-names></name></person-group><article-title>Differing risk of cancer death among patients with pathologic T3a renal cell carcinoma: Identification of risk categories according to fat infiltration and renal vein thrombosis</article-title><source>Clin. Genitourin. Cancer</source><year>2013</year><volume>11</volume><fpage>451</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1016/j.clgc.2013.05.006</pub-id><pub-id pub-id-type="pmid">23816525</pub-id></element-citation></ref><ref id="B9-diagnostics-10-00154"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brookman-May</surname><given-names>S.D.</given-names></name><name><surname>May</surname><given-names>M.</given-names></name><name><surname>Wolff</surname><given-names>I.</given-names></name><name><surname>Zigeuner</surname><given-names>R.</given-names></name><name><surname>Hutterer</surname><given-names>G.C.</given-names></name><name><surname>Cindolo</surname><given-names>L.</given-names></name><name><surname>Schips</surname><given-names>L.</given-names></name><name><surname>De Cobelli</surname><given-names>O.</given-names></name><name><surname>Rocco</surname><given-names>B.</given-names></name><name><surname>De Nunzio</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Evaluation of the prognostic significance of perirenal fat invasion and tumor size in patients with pT1-pT3a localized renal cell carcinoma in a comprehensive multicenter study of the CORONA project. Can we improve prognostic discrimination for patients with stage pT3a tumors?</article-title><source>Eur. Urol.</source><year>2015</year><volume>67</volume><fpage>943</fpage><lpage>951</lpage><pub-id pub-id-type="pmid">25684695</pub-id></element-citation></ref><ref id="B10-diagnostics-10-00154"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waalkes</surname><given-names>S.</given-names></name><name><surname>Merseburger</surname><given-names>A.S.</given-names></name><name><surname>Herrmann</surname><given-names>T.R.</given-names></name><name><surname>Kramer</surname><given-names>M.W.</given-names></name><name><surname>Wegener</surname><given-names>G.</given-names></name><name><surname>Rustemeier</surname><given-names>J.</given-names></name><name><surname>Hofmann</surname><given-names>R.</given-names></name><name><surname>Kuczyk</surname><given-names>M.A.</given-names></name><name><surname>Schrader</surname><given-names>A.J.</given-names></name></person-group><article-title>Urinary collecting system invasion is no independent prognostic factor in renal cell carcinoma</article-title><source>World J. Urol.</source><year>2010</year><volume>28</volume><fpage>283</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1007/s00345-010-0526-6</pub-id><pub-id pub-id-type="pmid">20237784</pub-id></element-citation></ref><ref id="B11-diagnostics-10-00154"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Gu</surname><given-names>L.</given-names></name><name><surname>Xie</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Invasion of the urinary collecting system is an independent prognostic factor in pT3 renal cell carcinoma</article-title><source>Urol. Oncol.</source><year>2016</year><volume>34</volume><fpage>293</fpage><pub-id pub-id-type="doi">10.1016/j.urolonc.2016.02.019</pub-id><pub-id pub-id-type="pmid">27017284</pub-id></element-citation></ref><ref id="B12-diagnostics-10-00154"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ball</surname><given-names>M.W.</given-names></name><name><surname>Gorin</surname><given-names>M.A.</given-names></name><name><surname>Harris</surname><given-names>K.T.</given-names></name><name><surname>Curtiss</surname><given-names>K.M.</given-names></name><name><surname>Netto</surname><given-names>G.J.</given-names></name><name><surname>Pavlovich</surname><given-names>C.P.</given-names></name><name><surname>Pierorazio</surname><given-names>P.M.</given-names></name><name><surname>Allaf</surname><given-names>M.E.</given-names></name></person-group><article-title>Extent of renal vein invasion influences prognosis in patients with renal cell carcinoma</article-title><source>BJU Int.</source><year>2016</year><volume>118</volume><fpage>112</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1111/bju.13349</pub-id><pub-id pub-id-type="pmid">26456548</pub-id></element-citation></ref><ref id="B13-diagnostics-10-00154"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Gu</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Influence of tumor size on oncological outcomes of pathological T3aN0M0 renal cell carcinoma treated by radical nephrectomy</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e173953</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0173953</pub-id><pub-id pub-id-type="pmid">28288191</pub-id></element-citation></ref><ref id="B14-diagnostics-10-00154"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minervini</surname><given-names>A.</given-names></name><name><surname>di Cristofano</surname><given-names>C.</given-names></name><name><surname>Lapini</surname><given-names>A.</given-names></name><name><surname>Marchi</surname><given-names>M.</given-names></name><name><surname>Lanzi</surname><given-names>F.</given-names></name><name><surname>Giubilei</surname><given-names>G.</given-names></name><name><surname>Tosi</surname><given-names>N.</given-names></name><name><surname>Tuccio</surname><given-names>A.</given-names></name><name><surname>Mancini</surname><given-names>M.</given-names></name><name><surname>della Rocca</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Histopathologic analysis of peritumoral pseudocapsule and surgical margin status after tumor enucleation for renal cell carcinoma</article-title><source>Eur. Urol.</source><year>2009</year><volume>55</volume><fpage>1410</fpage><lpage>1418</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2008.07.038</pub-id><pub-id pub-id-type="pmid">18692300</pub-id></element-citation></ref><ref id="B15-diagnostics-10-00154"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utsunomiya</surname><given-names>N.</given-names></name><name><surname>Kono</surname><given-names>Y.</given-names></name><name><surname>Matsumoto</surname><given-names>K.</given-names></name><name><surname>Sumiyoshi</surname><given-names>T.</given-names></name><name><surname>Masuda</surname><given-names>N.</given-names></name><name><surname>Shiraishi</surname><given-names>Y.</given-names></name><name><surname>Negoro</surname><given-names>H.</given-names></name><name><surname>Tsunemori</surname><given-names>H.</given-names></name><name><surname>Sugino</surname><given-names>Y.</given-names></name><name><surname>Okubo</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Risk factors for recurrence in pT3aN0M0 renal cell carcinoma according to 2009 TNM classification</article-title><source>Hinyokika Kiyo</source><year>2014</year><volume>60</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">24594765</pub-id></element-citation></ref><ref id="B16-diagnostics-10-00154"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>S.H.</given-names></name><name><surname>Kim</surname><given-names>J.K.</given-names></name><name><surname>Park</surname><given-names>J.</given-names></name><name><surname>Jeon</surname><given-names>H.J.</given-names></name><name><surname>Yoon</surname><given-names>M.Y.</given-names></name><name><surname>Jeong</surname><given-names>C.W.</given-names></name><name><surname>Ku</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>H.H.</given-names></name><name><surname>Kwak</surname><given-names>C.</given-names></name></person-group><article-title>Pathological T3a Upstaging of Clinical T1 Renal Cell Carcinoma: Outcomes According to Surgical Technique and Predictors of Upstaging</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0166183</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0166183</pub-id><pub-id pub-id-type="pmid">27861519</pub-id></element-citation></ref><ref id="B17-diagnostics-10-00154"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C.</given-names></name><name><surname>You</surname><given-names>D.</given-names></name><name><surname>Yoo</surname><given-names>S.</given-names></name><name><surname>Song</surname><given-names>C.</given-names></name><name><surname>Hong</surname><given-names>B.</given-names></name><name><surname>Hong</surname><given-names>J.H.</given-names></name><name><surname>Ahn</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>C.S.</given-names></name></person-group><article-title>Oncological outcomes of patients with incidental pathological T3a stage small renal cell carcinoma after partial nephrectomy</article-title><source>J. Cancer Res. Clin. Oncol.</source><year>2016</year><volume>142</volume><fpage>1651</fpage><lpage>1657</lpage><pub-id pub-id-type="doi">10.1007/s00432-016-2172-x</pub-id><pub-id pub-id-type="pmid">27193144</pub-id></element-citation></ref><ref id="B18-diagnostics-10-00154"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donat</surname><given-names>S.M.</given-names></name><name><surname>Diaz</surname><given-names>M.</given-names></name><name><surname>Bishoff</surname><given-names>J.T.</given-names></name><name><surname>Coleman</surname><given-names>J.A.</given-names></name><name><surname>Dahm</surname><given-names>P.</given-names></name><name><surname>Derweesh</surname><given-names>I.H.</given-names></name><name><surname>Herrell</surname><given-names>S.D.</given-names></name><name><surname>Hilton</surname><given-names>S.</given-names></name><name><surname>Jonasch</surname><given-names>E.</given-names></name><name><surname>Lin</surname><given-names>D.W.</given-names></name><etal/></person-group><article-title>Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline</article-title><source>J. Urol.</source><year>2013</year><volume>190</volume><fpage>407</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2013.04.121</pub-id><pub-id pub-id-type="pmid">23665399</pub-id></element-citation></ref><ref id="B19-diagnostics-10-00154"><label>19.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>National Comprehensive Cancer Network</collab></person-group><article-title>NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer 2</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf">https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-07-21">(accessed on 21 July 2019)</date-in-citation></element-citation></ref><ref id="B20-diagnostics-10-00154"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ljungberg</surname><given-names>B.</given-names></name><name><surname>Albiges</surname><given-names>L.</given-names></name><name><surname>Abu-Ghanem</surname><given-names>Y.</given-names></name><name><surname>Bensalah</surname><given-names>K.</given-names></name><name><surname>Dabestani</surname><given-names>S.</given-names></name><name><surname>Fernandez-Pello</surname><given-names>S.</given-names></name><name><surname>Giles</surname><given-names>R.H.</given-names></name><name><surname>Hofmann</surname><given-names>F.</given-names></name><name><surname>Hora</surname><given-names>M.</given-names></name><name><surname>Kuczyk</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update</article-title><source>Eur. Urol.</source><year>2019</year><volume>75</volume><fpage>799</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2019.02.011</pub-id><pub-id pub-id-type="pmid">30803729</pub-id></element-citation></ref><ref id="B21-diagnostics-10-00154"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broncy</surname><given-names>L.</given-names></name><name><surname>Paterlini-Brechot</surname><given-names>P.</given-names></name></person-group><article-title>Circulating Tumor Cells for the Management of Renal Cell Carcinoma</article-title><source>Diagnostics</source><year>2018</year><volume>8</volume><elocation-id>63</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics8030063</pub-id><pub-id pub-id-type="pmid">30177639</pub-id></element-citation></ref><ref id="B22-diagnostics-10-00154"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>C.G.</given-names></name><name><surname>Moser</surname><given-names>T.</given-names></name><name><surname>Mouliere</surname><given-names>F.</given-names></name><name><surname>Field-Rayner</surname><given-names>J.</given-names></name><name><surname>Eldridge</surname><given-names>M.</given-names></name><name><surname>Riediger</surname><given-names>A.L.</given-names></name><name><surname>Chandrananda</surname><given-names>D.</given-names></name><name><surname>Heider</surname><given-names>K.</given-names></name><name><surname>Wan</surname><given-names>J.C.M.</given-names></name><name><surname>Warren</surname><given-names>A.Y.</given-names></name><etal/></person-group><article-title>Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors</article-title><source>Genome Med.</source><year>2020</year><volume>12</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1186/s13073-020-00723-8</pub-id><pub-id pub-id-type="pmid">32111235</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="diagnostics-10-00154-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Schematic representation of the study workflow This study included 424 patients who underwent unilateral RN or PN for RCC at our institute between 2007 and 2017. Of these, 91 patients with pT3aN0M0 RCC were identified. Information regarding the preoperative conditions was obtained retrospectively by reviewing the medical records and laboratory blood tests. Data on gender, age, comorbidities, and C-reactive protein were obtained. Preoperative imaging evaluation and TNM classification including the presence or absence of cd-RVT were performed by a skilled uro-radiologist. The operation was performed by skilled urologists at our hospital. Postoperative sample evaluation was performed by a pathologist specializing in the urology. After establishing the exclusion criteria, 91 cases were identified. cd-RVT, clinically detected renal vein thrombus; INF, infiltration; LVI, lymphovascular invasion; UCSI, urinary collecting system invasion; RN, radical nephrectomy; PN, partial nephrectomy.</p></caption><graphic xlink:href="diagnostics-10-00154-g001"/></fig><fig id="diagnostics-10-00154-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Recurrence-free survival and cancer-specific survival probabilities for pT3aN0M0 RCC. RFS and CSS were estimated using the Kaplan&#x02013;Meier method. (<bold>a</bold>) The 3-, 5-, and 10-year RFS rates were 71.4%, 65.3%, and 59.3%, respectively. (<bold>b</bold>) The 3-, 5-, and 10-year CSS rates were 93.8%, 88.4%, and 81.1%, respectively RFS, recurrence-free survival; CSS, cancer-specific survival.</p></caption><graphic xlink:href="diagnostics-10-00154-g002"/></fig><fig id="diagnostics-10-00154-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Recurrence-free survival probabilities for four main factors; tumor size, urinary collecting system invasion, pathological invasion sites, and clinically detected renal vein thrombus. Patients with tumor size &#x0003e; 7 cm (<bold>a</bold>); UCSI (<bold>b</bold>); three invasion sites (<bold>c</bold>); or cd-RVT (<bold>d</bold>) had a significantly higher risk of recurrence than those without. RFS, recurrence-free survival; UCSI, urinary collecting system invasion; cd-RVT, clinically detected renal vein thrombus.</p></caption><graphic xlink:href="diagnostics-10-00154-g003"/></fig><fig id="diagnostics-10-00154-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Cancer-specific survival probabilities for four main factors: tumor size, urinary collecting system invasion, pathological invasion sites, and clinically detected renal vein thrombus. Patients with three invasion sites (<bold>c</bold>) or cd-RVT (<bold>d</bold>) had a significantly higher risk than those without. On the other hand, there was no significant difference in CSS between patients with tumor size &#x02264; 7 cm or &#x0003e;7 cm (<bold>a</bold>). There was no statistically significant difference in CSS between patients with UCSI or without UCSI (<bold>b</bold>). CSS, cancer-specific survival; UCSI, urinary collecting system invasion; cd-RVT, clinically detected renal vein thrombus.</p></caption><graphic xlink:href="diagnostics-10-00154-g004"/></fig><table-wrap id="diagnostics-10-00154-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">diagnostics-10-00154-t001_Table 1</object-id><label>Table 1</label><caption><p>Clinicopathological information.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Variables</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Patients</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">%</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(n = 91)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gender</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male<break/>Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65<break/>26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71.4<break/>28.6</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median (Range)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68 (41&#x02013;87)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Follow-up (month)</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median (Range)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48 (6&#x02013;134)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Charlson comorbidity index</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0<break/>&#x02265;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41<break/>50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45.1<break/>54.9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CRP</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x0003c;0.5<break/>&#x02265;0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">61<break/>30</td><td align="center" valign="middle" rowspan="1" colspan="1">67.0<break/>33.0</td></tr><tr><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical T stage</td><td align="right" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">cT1a/1b<break/>cT2a/2b<break/>cT3a/3b/3c<break/>cT4</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">14/21<break/>7/9<break/>32/6/0<break/>2</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">15.4/23.1<break/>7.7/9.9<break/>35.2/6.6/0<break/>2.2</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinically detected renal vein thrombus</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;<break/>+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74<break/>17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.3<break/>18.7</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Type of Surgery</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RN<break/>PN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84<break/>7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.3<break/>7.7</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Tumor size (cm)</td><td align="right" valign="middle" rowspan="1" colspan="1">Median (Range)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.4 (1.4&#x02013;14)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02264;7<break/>&#x0003e;7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62<break/>29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.1<break/>31.9</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Histological type</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clear cell<break/>Papillary<break/>Chromophobe<break/>others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74<break/>11<break/>3<break/>3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.3<break/>12.1<break/>3.3<break/>3.3</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fuhrman Grade</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#x02013;2<break/>3&#x02013;4<break/>NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39<break/>39<break/>13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42.9<break/>42.9<break/>14.2</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">INF</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">a<break/>b<break/>c</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16<break/>73<break/>2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.6<break/>82.4<break/>2.2</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LVI</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;<break/>+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29<break/>61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.9<break/>67.0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Urinary collecting system invasion</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;<break/>+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69<break/>22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75.8<break/>24.2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pathologically invasion subgroups</td><td align="right" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">Renal vein invasion</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;<break/>+</td><td align="center" valign="middle" rowspan="1" colspan="1">45<break/>46</td><td align="center" valign="middle" rowspan="1" colspan="1">49.5<break/>50.5</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">Peri renal fat invasion</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;<break/>+</td><td align="center" valign="middle" rowspan="1" colspan="1">57<break/>34</td><td align="center" valign="middle" rowspan="1" colspan="1">62.6<break/>37.4</td></tr><tr><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Renal sinus fat invasion</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;<break/>+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36<break/>55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.6<break/>60.4</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pathologically invasion number of subgroups</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1<break/>2<break/>3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56<break/>26<break/>9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.5<break/>28.6<break/>9.9</td></tr></tbody></table><table-wrap-foot><fn><p>CRP, C-reactive protein; RN, radical nephrectomy; PN, partial nephrectomy; INF, infiltrative growth; LVI, lymphovascular invasion.</p></fn></table-wrap-foot></table-wrap><table-wrap id="diagnostics-10-00154-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">diagnostics-10-00154-t002_Table 2</object-id><label>Table 2</label><caption><p>Univariate and multivariate cox regression analyses for RFS (* statistically significant).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Variables</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Univariate Analysis</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Multivariate Analysis</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gender</td><td align="right" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.37</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.61&#x02013;3.57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02265;70</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.26</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.72&#x02013;3.37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CRP</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x0003c;0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.009 *</td><td rowspan="2" colspan="3" align="center" valign="middle" style="border-bottom:solid thin">not included</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.32&#x02013;7.06</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">clinically detected renal vein thrombus</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.0074 *</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">&#x0003c;0.001 *</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.45&#x02013;11.37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.86&#x02013;9.01</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Fuhrman Grade</td><td align="right" valign="middle" rowspan="1" colspan="1">G1,2</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" colspan="1">0.015 *</td><td rowspan="2" colspan="3" align="center" valign="middle">not included</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">G3,4</td><td align="center" valign="middle" rowspan="1" colspan="1">2.97</td><td align="center" valign="middle" rowspan="1" colspan="1">1.23&#x02013;7.17</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">INF</td><td align="right" valign="middle" rowspan="1" colspan="1">a</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" colspan="1">0.011 *</td><td rowspan="2" colspan="3" align="center" valign="middle">not included</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">b/c</td><td align="center" valign="middle" rowspan="1" colspan="1">3.53</td><td align="center" valign="middle" rowspan="1" colspan="1">1.33&#x02013;9.38</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LVI</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" colspan="1">0.03 *</td><td rowspan="2" colspan="3" align="center" valign="middle">not included</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">2.39</td><td align="center" valign="middle" rowspan="1" colspan="1">1.06&#x02013;5.37</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Necrosis</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" colspan="1">0.0003 *</td><td rowspan="2" colspan="3" align="center" valign="middle">not included</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">4.26</td><td align="center" valign="middle" rowspan="1" colspan="1">1.96&#x02013;9.28</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Histological classification</td><td align="right" valign="middle" rowspan="1" colspan="1">non-ccRCC</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" colspan="1">0.44</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">ccRCC</td><td align="center" valign="middle" rowspan="1" colspan="1">0.64</td><td align="center" valign="middle" rowspan="1" colspan="1">0.21&#x02013;1.97</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sarcomatoid variant</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.94</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.13&#x02013;8.77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Tumor size</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02264;7</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.013 *</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.004 *</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.98</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.26&#x02013;7.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.46&#x02013;7.31</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Urinary collecting system invasion</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">&#x0003c;0.0001 *</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.001 *</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.86</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.10&#x02013;25.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.86&#x02013;9.76</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pathologically renal vein invasion</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" colspan="1">0.022 *</td><td rowspan="2" colspan="3" align="center" valign="middle">not included</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">2.42</td><td align="center" valign="middle" rowspan="1" colspan="1">1.13&#x02013;5.21</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pathologically peri renal fat invasion</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" colspan="1">0.21</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">1.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.74&#x02013;3.73</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pathologically renal sinus fat invasion</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.22</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.612</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.27&#x02013;1.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pathologically invasion numbers of subgroups</td><td align="right" valign="middle" rowspan="1" colspan="1">1/2</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.0008 *</td><td rowspan="2" colspan="3" align="center" valign="middle" style="border-bottom:solid thin">not included</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.03&#x02013;67.1</td></tr></tbody></table><table-wrap-foot><fn><p>HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein; INF, infiltration; LVI, lymphovascular invasion; ccRCC, clear cell renal cell carcinoma not included. We limited the number of variables three for the multivariable analysis to prevent overfitting the model because of the small number of events (26 events).</p></fn></table-wrap-foot></table-wrap><table-wrap id="diagnostics-10-00154-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">diagnostics-10-00154-t003_Table 3</object-id><label>Table 3</label><caption><p>Univariate analyses for CSS (* statistically significant).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Variables</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Univariate Analysis</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HR</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95% CI</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gender</td><td align="right" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.25</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.54&#x02013;9.75</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02265;70</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.81</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.33&#x02013;4.08</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CRP</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x0003c;0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.28</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.55&#x02013;7.64</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">clinically renal vein thrombus</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.049 *</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.98&#x02013;26.44</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Fuhrman Grade</td><td align="right" valign="middle" rowspan="1" colspan="1">G1,2</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" colspan="1">0.07</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">G3,4</td><td align="center" valign="middle" rowspan="1" colspan="1">4.49</td><td align="center" valign="middle" rowspan="1" colspan="1">0.85&#x02013;23.72</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">INF</td><td align="right" valign="middle" rowspan="1" colspan="1">a</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" colspan="1">0.15</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">b/c</td><td align="center" valign="middle" rowspan="1" colspan="1">3.38</td><td align="center" valign="middle" rowspan="1" colspan="1">0.66&#x02013;17.42</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LVI</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" colspan="1">0.14</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">2.72</td><td align="center" valign="middle" rowspan="1" colspan="1">0.71&#x02013;10.33</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Necrosis</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" colspan="1">0.48</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">1.56</td><td align="center" valign="middle" rowspan="1" colspan="1">0.45&#x02013;5.42</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Histological classification</td><td align="right" valign="middle" rowspan="1" colspan="1">non-ccRCC</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" colspan="1">0.30</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">ccRCC</td><td align="center" valign="middle" rowspan="1" colspan="1">0.42</td><td align="center" valign="middle" rowspan="1" colspan="1">0.10&#x02013;2.15</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sarcomatoid variant</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.5</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01&#x02013;7.56</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">tumor size</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02264;7</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.07</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.87&#x02013;12.11</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Urinary collecting system invasion</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.07</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.86&#x02013;22.01</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pathologically renal vein invasion</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" colspan="1">0.4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">1.69</td><td align="center" valign="middle" rowspan="1" colspan="1">0.48&#x02013;5.86</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pathologically peri renal fat invasion</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" colspan="1">0.21</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="right" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">9.1</td><td align="center" valign="middle" rowspan="1" colspan="1">2.42&#x02013;34.</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pathologically renal sinus fat invasion</td><td align="right" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.27</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.39&#x02013;5.06</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pathologically invasion of subgroups</td><td align="right" valign="middle" rowspan="1" colspan="1">1/2</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">&#x0003c;0.0001 *</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91&#x02013;13,500</td></tr></tbody></table><table-wrap-foot><fn><p>HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein; INF, infiltration; LVI, lymphovascular invasion; ccRCC, clear cell renal cell carcinoma.</p></fn></table-wrap-foot></table-wrap><table-wrap id="diagnostics-10-00154-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">diagnostics-10-00154-t004_Table 4</object-id><label>Table 4</label><caption><p>Correlation between presence of UCSI and Hematuria levels of Total/Micro/Macro.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Spearman <italic>r</italic></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hematuria</td><td align="center" valign="middle" rowspan="1" colspan="1">0.54</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Micro Hematuria</td><td align="center" valign="middle" rowspan="1" colspan="1">0.43</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Macro Hematuria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody></table><table-wrap-foot><fn><p>UCSI, urinary collecting system invasion.</p></fn></table-wrap-foot></table-wrap></floats-group></article>